BC Week In Review | Mar 30, 2018
Clinical News

Allecra reports Phase II data for AAI101 combo to treat cUTI

Allecra Therapeutics GmbH (Lörrach, Germany) reported top-line data from the Phase II CACTUS trial in 45 hospitalized adults with complicated urinary tract infections (cUTIs), including pyelonephritis, showing that AAI101 in combination with cefepime was well...
BC Innovations | Jun 28, 2012
Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Pseudomonas Extended-spectrum b-lactamase (ESBL); Pseudomonas aeruginosa OXA-28 Bacterial cell culture studies suggest blocking the migration of a gene cassette in...
BioCentury | Dec 21, 2009

Ebb & Flow

The 2004 merger of Fujisawa Pharmaceutical Co. Ltd. and Yamanouchi Pharmaceutical Co. Ltd. to form Astellas Pharma Inc . (Tokyo:4503) has led to big payoffs in the last two weeks for Calixa Therapeutics Inc. and Gloucester...
BC Week In Review | Sep 28, 2009
Clinical News

Basilea preclinical data

In a mouse model of septicemia, BAL30072 alone or in combination with meropenem was effective against all tested strains of Acinetobacter baumanii, Escherichia coli, Enterobacter cloacae and Pseudomonas aeruginosa. In a mouse model of urinary...
BioCentury | Aug 17, 2009
Emerging Company Profile

Calixa: Bettering cephalosporin

Calixa Therapeutics Inc. is developing an in-licensed cephalosporin it says is more potent against multi-drug resistant strains of Pseudomonas aeruginosa than all other available beta lactams. The lead compound, CXA-101 , and two follow-ons are in...
BC Week In Review | Nov 10, 2008
Clinical News

Accelr8 Technology preclinical data

In 126 bacterial strains, Accelr8's ESBL test had 96% sensitivity and 96% specificity in detecting extended-spectrum beta lactamase (ESBL)-resistant bugs. The test produced results in 90-180 minutes. Data were presented at the Interscience Conference on...
BC Week In Review | Dec 17, 2007
Company News

NHS Innovations London Ltd., University Hospital Lewisham sales and marketing update

NHS Innovations and the university launched their ESBL Selective Broth diagnostic test for the rapid detection of extended-spectrum beta lactamase (ESBL)-producing bacteria. NHS Innovations London Ltd. , London, U.K.   University Hospital Lewisham , London, U.K.  ...
BC Week In Review | Feb 19, 2007
Company News

bioMerieux sales and marketing update

BIM launched its chromID vancomycin resistant enterococci (VRE) and chromID extended-spectrum beta-lactamase ( ESBL ) chromogenic culture media outside the U.S. The company also launched its DiversiLab system for automated microbial genotyping in Europe and Asia. BIM...
BC Week In Review | Jan 2, 2006
Clinical News

Wyeth preclinical data

In vitro data shows that tigecycline, a glycylcycline antibiotic, was effective against many resistant Gram-negative bacteria including extended-spectrum beta-lactamase ( ESBL ) producing bacterias. Tygacil tigecycline is approved in the U.S. for complicated intra-abdominal infections (cIAI) and...
Items per page:
1 - 9 of 9